STOCK TITAN

Toronto Stock Exchange, Theratechnologies Inc., View From The C-Suite

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Paul Lévesque, President and CEO of Hamilton Thorne Ltd., shares his Company's story in an interview with TMX Group.
Positive
  • Positive: The interview provides insight into Hamilton Thorne Ltd.'s perspective in the current business environment.
Negative
  • None.

TORONTO, Aug. 21, 2023 /PRNewswire/ - Paul Lévesque, President and Chief Executive Officer, Hamilton Thorne Ltd. ("Theratechnologies", the "Company", or "we") (TSX: TH) shares his Company's story in an interview with TMX Group.

The View From The C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest View From The C-Suite visit https://www.tmxmoney.com/en/csuite.html.

About Theratechnologies Inc. (TSX: TH)

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

CNW sponsored announcement. To learn more visit www.newswire.ca.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/toronto-stock-exchange-theratechnologies-inc-view-from-the-c-suite-301905942.html

SOURCE Toronto Stock Exchange

Theratechnologies Inc. Common

NASDAQ:THTX

THTX Rankings

THTX Latest News

THTX Stock Data

59.77M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.